WEBULL
WebtradeDownload

Is Viking Therapeutics (VKTX) Trading At A Premium To Book Value?

Simply Wall St · 3d ago

Viking Therapeutics has seen its share price pull back sharply in recent months after a strong multi year run, which puts fresh focus on whether today's valuation lines up with the assets on its balance sheet. With book value in the spotlight, the question is how much investors are currently paying for each dollar of net assets given the latest shift in sentiment.

  • Over the past 5 years the stock has returned about 285.4%, so a lot of expectations are now wrapped up in the price that need to be weighed against what the company actually owns.
  • Management's push on the oral obesity candidate VK2735 and the associated rise in research and development spending can reshape future cash needs and may support a different relationship between Viking Therapeutics' book value and its market valuation.
  • Your read on Viking Therapeutics is one view; the desks covering it have another. See what analysts think Viking Therapeutics's shares could be worth.

The issue now is whether Viking Therapeutics' recent share price, after the pullback, is adequately supported by its book value compared with the industry average.

If you are comparing Viking Therapeutics with similar opportunities based on valuation and balance sheet quality, a focused stock screen can help you broaden the field by using solid balance sheet and fundamentals stocks screener (24 results).

Does Viking Therapeutics Look Pricey on Book Value?

A price to book lens fits Viking Therapeutics because the business is still loss making and investors are paying mainly for its cash and pipeline rather than current earnings. On this measure, the shares trade on a P/B of about 7.2x, compared with a Biotechs industry average near 2.0x and a peer group around 3.9x, so the stock changes hands at a clear premium to both groups.

Despite the recent pullback after management defended the oral VK2735 program and spending plans, Viking Therapeutics still screens as overvalued against typical biotech book value multiples. This suggests investors are assigning a high valuation to future trial outcomes relative to the present balance sheet. Anyone considering the shares needs to weigh how much confidence they have in those clinical milestones, since at this price most of the value sits in expectations rather than in current net assets. Explore the numbers behind Viking Therapeutics's P/B valuation.

NasdaqCM:VKTX P/B Ratio as at Oct 2026
NasdaqCM:VKTX P/B Ratio as at Oct 2026

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Viking Therapeutics pick up where the valuation puzzle leaves off by spelling out which future paths for growth, margins and earnings would make the current share price look either stretched or conservative. Instead of giving a single figure, they unpack the assumptions behind that number so you can see which future scenarios Viking Therapeutics' valuation depends on and track whether real world developments support it or not on the Community page.

One of the top community narratives on Viking Therapeutics: 80% undervalued

"The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path…"

Discover why this Narrative puts Viking Therapeutics at 80% undervalued.

Viking Therapeutics' valuation story misses one pressing question

Price tags and book values tell only part of the story for Viking Therapeutics, because our broader checks have flagged specific concerns that could change how you view the risk side of this thesis. Take a closer look at 4 warning signs (1 major) before settling on a valuation.